Skip to main navigation
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
 
 
  • Home
  • Our Company
    • About Iovance Biotherapeutics
    • Management
    • Board of Directors
    • Research Partners & Collaborators
  • Our Science
    • About TIL
    • Our T-cell Therapy Platforms
    • Scientific Publications & Presentations
    • Next Generation Research
  • Our Technology
    • Iovance Cell
      Therapy Center
    • Manufacturing
    • Intellectual Property
  • Our Pipeline
    • Clinical Pipeline
    • Clinical Trials
    • Expanded Access Policy
  • Careers
    • Current Opportunities
    • Our Culture
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn

Press Releases

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Ownership Summary
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Earnings Estimates
  • Fundamentals
    • Snapshot
    • Trading Statistics
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Ratios
  • Corporate Governance
    • Governance Highlights
    • Committee Composition
Investor Toolkit
  • Print Page
  • RSS
  • Email Alerts
  • Sep 27, 2023 Iovance Biotherapeutics to Present Clinical and Pre-Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapies at Society for Tumor Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
    Four-year Analysis of C-144-01 Trial Cohorts 2 and 4 SAN CARLOS, Calif. , Sept. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for
    View
  • Sep 22, 2023 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    SAN CARLOS, Calif. , Sept. 22, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on September
    View
  • Sep 14, 2023 U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma
    Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to Expedite Remaining Review SAN CARLOS, Calif. , Sept.
    View
  • Sep 07, 2023 Iovance Biotherapeutics to Present at 2023 Wells Fargo Healthcare Conference
    SAN CARLOS, Calif. , Sept. 07, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior
    View
  • Aug 18, 2023 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    SAN CARLOS, Calif. , Aug. 18, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on August 17,
    View
  • Aug 08, 2023 Iovance Biotherapeutics Reports Second Quarter and First Half 2023 Financial Results and Corporate Updates
    FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 Preparing for Potential Commercial Launch of Lifileucel as First Approved TIL Therapy in 2023 Post-Anti-PD-1 Non-Small
    View
  • Jul 25, 2023 Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy at IASLC 2023 World Conference on Lung Cancer
    Oral Presentation of Cohort 3A Data from IOV-COM-202 Phase 2 Clinical Trial of LN-145 in Combination with Pembrolizumab in Anti-PD1-naïve Advanced (metastatic or unresectable) Non-Small Cell Lung Cancer (NSCLC) SAN CARLOS, Calif. , July 25, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
    View
  • Jul 24, 2023 Iovance Biotherapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, August 8, 2023
    SAN CARLOS, Calif. , July 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter 2023
    View
  • Jul 21, 2023 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
    SAN CARLOS, Calif. , July 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on July 20,
    View
  • Jul 13, 2023 Iovance Biotherapeutics Announces Closing of $172.5 Million Common Stock Public Offering
    Offering Includes Exercise in Full of the Underwriters’ Option to Purchase an Additional 3 Million Shares of Common Stock SAN CARLOS, Calif. , July 13, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering
    View
  • Jul 10, 2023 Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $150 Million of Common Stock
    SAN CARLOS, Calif. , July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics , Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today
    View
  • Jul 10, 2023 Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
    SAN CARLOS, Calif. , July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics , Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today
    View
  • Jul 10, 2023 Iovance Biotherapeutics Announces Regulatory and Clinical Updates for TIL Therapy in Advanced Non-Small Cell Lung Cancer
    Positive FDA Feedback Supports IOV-LUN-202 Trial Design for Accelerated Approval  of TIL Therapy in Post-Anti-PD-1 Advanced Non-Small Cell Lung Cancer (NSCLC) Preliminary Clinical Data in Post-Anti-PD-1 NSCLC Demonstrated a 26.1% Objective Response Rate (ORR) in Registrational IOV-LUN-202 Trial SAN
    View
  • Jun 20, 2023 Iovance Biotherapeutics to Host Virtual Roundtable with Key Opinion Leaders to Discuss Melanoma Treatment Landscape
    Investor Conference Call and Webcast on June 26 at 5:00 p.m. ET SAN CARLOS, Calif. , June 20, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL)
    View
  • Jun 15, 2023 Iovance Biotherapeutics Announces First Patient Randomized in Phase 3 TILVANCE-301 Trial in Frontline Advanced Melanoma
    Global Trial of Iovance TIL Therapy Lifileucel in Combination with Pembrolizumab SAN CARLOS, Calif. , June 15, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating
    View
  • Jun 09, 2023 Iovance Biotherapeutics to Present at Jefferies Global Healthcare Conference
    SAN CARLOS, Calif. , June 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the Jefferies Global Healthcare Conference :
    View
  • May 26, 2023 Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
    Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date of November 25, 2023 First Potential Approval of an Individualized, One-Time Cell Therapy for Patients with Advanced Melanoma SAN CARLOS, Calif. , May 26, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
    View
  • May 09, 2023 Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
    First Biologics License Application (BLA) Submission Completed in March 2023 Commercial Readiness Activities on track to Support Potential Commercial Launch of Lifileucel in 2023 SAN CARLOS, Calif. , May 09, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
    View
  • May 02, 2023 Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023
    SAN CARLOS, Calif. , May 02, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter 2023 financial results on Tuesday, May 9, 2023 .
    View
  • Apr 24, 2023 Iovance Biotherapeutics to Present at Upcoming Conferences
    SAN CARLOS, Calif. , April 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: Chardan's 7 th Annual
    View
  • Mar 24, 2023 Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma
    First TIL Therapy BLA Submission to U.S. Food and Drug Administration SAN CARLOS, Calif. , March 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced it has completed its
    View
  • Mar 01, 2023 Iovance Biotherapeutics to Present at Upcoming Conferences
    SAN CARLOS, Calif. , March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following conferences: H.C.
    View
  • Feb 28, 2023 Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates
    First Biologics License Application (BLA) Submission on Track to Complete in 1Q23 SAN CARLOS, Calif. , Feb. 28, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating
    View
  • Feb 21, 2023 Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023
    SAN CARLOS, Calif. , Feb. 21, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023 .
    View
  • Jan 23, 2023 Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
    Acquisition of Worldwide Rights to Proleukin ® Provides Immediate and Ongoing Revenue and Secures IL-2 Supply for Clinical and Future Commercial TIL Therapy Positive FDA Feedback on Phase 3 Confirmatory Study in Frontline Advanced (Metastatic or Unresectable) Melanoma Positive Clinical Data in
    View
Iovance Biotherapeutics
  • News
  • Investors
  • Email Alerts
  • Patients
  • Join Us
  • Contact Us
  • Site Map
  • Contact Us
  • Twitter
  • LinkedIn
© 2023 IOVANCE Biotherapeutics, Inc. All Rights Reserved. IOVANCE logo is a trademark owned
by IOVANCE Biotherapeutics, Inc.
  • Privacy Notice
  • Terms of Use